The efficacy of early versus delayed P2Y12 inhibition in percutaneous coronary intervention for ST-elevation myocardial infarction: a systematic review and meta-analysis

EuroIntervention 2018;14:78-85 published online February 2018. DOI: 10.4244/EIJ-D-17-00852

Anne Bellemain-Appaix
Anne Bellemain-Appaix1,2, MD; Céline Bégué2,3, MD; Deepak L. Bhatt4, MD, MPH; Kenneth Ducci5, MD; Robert A. Harrington6, MD; Matthew Roe7, MD, MHS; Stephen D. Wiviott8, MD; Michel Cucherat9, MD, PhD; Johanne Silvain2,3, MD, PhD; Jean-Philippe Collet2,3, MD, PhD; François Bernasconi1, MD; Gilles Montalescot2,3*, MD, PhD; for the ACTION Study Group
1. Service de Cardiologie-Antibes Hospital, Antibes, France; 2. ACTION Study Group, Paris, France; 3. Sorbonne Université Paris 6, Institut de Cardiologie, INSERM UMRS-1166, Pitié-Salpêtrière Hospital (AP-HP), Paris, France; 4. Brigham and Women’s Hospita

Aims: The aim of this meta-analysis was to compare the benefit of “early” vs. “delayed” P2Y12 inhibition in patients undergoing percutaneous coronary intervent

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

adjunctive pharmacotherapyantithrombotic treatmentbleedingdeathmyocardial infarctionstemi
Read next article
A prospective randomised trial comparing the novel ridaforolimus-eluting BioNIR stent to the zotarolimus-eluting Resolute stent: six-month angiographic and one-year clinical results of the NIREUS trial

Latest news